PBYI Puma Biotechnology
- 4.000
- +0.010+0.25%
- 4.010
- +0.010+0.25%
Puma Biotechnology News
Puma Biotechnology (PBYI) Falls 38% in 3 Months: Here's Why
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced the release of abstracts on alisertib to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO
Implied Volatility Surging for Puma Biotechnology (PBYI) Stock Options
TD Cowen Sticks to Its Hold Rating for Puma Biotechnology (PBYI)
Express News | Puma Biotechnology Says Jury Verdict Was Entered In Favor Of Wyeth, And Against AstraZeneca; Jury Found '314 & '162 Patents To Be Infringed By AstraZeneca And Not Invalid, Awarded Plaintiffs $107.5M In Damages
Express News | Puma Biotechnology Inc - Jury Found '314 & '162 Patents to Be Infringed by AstraZeneca and Not Invalid, Awarded Plaintiffs $107.5 Mln in Damages
Express News | Puma Biotechnology Inc - Jury Verdict Was Entered in Favor of Wyeth, and Against AstraZeneca
Puma Biotech Surges Amid Wyeth Victory in Tagrisso Patent Case
Puma Posts Lower Earnings After Sales Suffer Currency Headwind
By Pierre Bertrand Puma reported a decline in first-quarter earnings after sales were hit by unfavorable currency effects. The German sporting-goods company said it made 87.3 million euros ($93.9 mi
Analysts Have Lowered Expectations For Puma Biotechnology, Inc. (NASDAQ:PBYI) After Its Latest Results
Puma Biotechnology First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Express News | HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $7 Price Target
Puma Biotechnology Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/03/2024 43.44% HC Wainwright & Co. → $7 Reiterates Buy → Buy 03/01/2024 43.44% HC Wainwright & Co. $8 →
Earnings Call Summary | Puma Biotechnology(PBYI.US) Q1 2024 Earnings Conference
The following is a summary of the Puma Biotechnology, Inc. (PBYI) Q1 2024 Earnings Call Transcript:Financial Performance:Puma Biotechnology reported a total revenue of $43.8 million for Q1 2024, which
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2024 Earnings Call Transcript
Puma Biotechnology (PBYI) Receives a Sell From Barclays
Buy Rating Affirmed for Puma Biotechnology Amid Strong Q1 Performance and Promising Outlook
Puma Biotechnology Inc (PBYI) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of ...
Puma Biotechnology Inc (PBYI) Reports Q1 Financial Results, Misses Analyst Revenue and EPS Forecasts
Puma Biotechnology Q1 2024 Adj EPS $(0.05) Beats $(0.22) Estimate, Sales $43.800M Beat $41.050M Estimate
Puma Biotechnology (NASDAQ:PBYI) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.22) by 77.27 percent. This is a 155.56 percent decrease over earnings o
Analysis
Price Target
No Data
